



Date: 23 November 2017

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

CLARIFICATION OF INCORRECT INFORMATION

Sydney, 23 November 2017: Noxopharm is pleased to clarify an inaccurate media report yesterday and subsequent ASX announcement that had the potential to misinform the market.

The media report inaccurately stated that experimental drug, NOX66, was developed by Dr Graham Kelly while an employee of Kazia Therapeutics (formerly Novogen, a company founded by Dr Kelly). That statement has been retracted and the report corrected to state the factual situation that NOX66 was developed by Dr Kelly before he became an employee of Novogen.

Noxopharm is the owner of the NOX66 intellectual property and strongly refutes any suggestion by any person that this is not the case.

.....

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of chemotherapy- and radiation-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs.

Investor & Corporate Enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 9299 9690
E: dfranks@fa.com.au

www.noxopharm.com